| |
Newsroom /
Health and Fitness
/
Healthcare
/
Ulcerative Colitis- Drug Pipeline Analysis and Market Forecasts to 2015
Ulcerative Colitis- Drug Pipeline Analysis and Market Forecasts to 2015
The Ulcerative Colitis Therapeutics Market is Projected to Show Reasonable Growth by 2015
Hyderabad,
AP,
India
(prbd.net)
22/12/2009
"The Ulcerative Colitis Therapeutics Market is estimated to grow reasonably by 5.1% annually for the next seven years to reach $1.9 billion by 2015. "
GlobalData estimates the global ulcerative colitis (UC) market was valued at $1.3 billion in 2008. It is estimated to grow reasonably by 5.1% annually for the next seven years to reach $1.9 billion by 2015. The growth will be driven by several factors like intensification in UC prevalence and expected approvals of biologics in the future. Barriers for the UC market include diagnostic limitations and a complex disease etiology, which moderately affect the growth of the market. These barriers can be overcome with technological advances in the field of drug discovery and disease diagnosis.
GlobalData has analyzed the current UC market landscape and found it to be a market dominated by me-too products of the ASA class of drugs to a remarkable extent. Currently seven branded products and several generics are available for the treatment of UC. Of all the seven branded drugs there is only one biologic, Remicade, which shows least cost effectiveness when compared to the other marketed products. Competition in the ulcerative colitis market is driven not only by product characteristics such as efficacy and safety profile, but also by market characteristics such as number of competitors, pricing, generics, and treatment flow indicators such as patient compliance and physician perceptions. Procter & Gamble (P&G), Santen pharmaceuticals, Salix Pharmaceuticals and Johnson & Johnson are the leading players of the global UC market. Together, these companies will account for approximately 61% of the global market share in 2009, the rest owned by the generic manufacturers. P&G remains the market leader with a share of approximately 23%. The global ulcerative colitis market has moderate levels of unmet need which can be fulfilled by the launch of safe and efficacious biologics in the future.
The current UC market is extremely competitive with only seven drugs approved. Apriso is the seventh drug after gaining approval for UC in 2009. The current market is dominated by me-too drugs of the ASA drug class. Remicade is the only biologic approved for UC, which leaves the market craving for efficient and safer biologics for the treatment of UC. Remicade dose not completely fulfill this need due to its low cost effectiveness. The others drugs like Apriso, Colazal, Pentasa and Lialda have moderate to high efficacy and safety and are fairly cost effective. Generics hold a share of 38% of revenues in the market and are the most cost effective of all the marketed products.
GlobalData, the industry analysis specialist, has released a new report, “Ulcerative Colitis – Drug Pipeline Analysis and Market Forecasts to 2015”. The report is an essential source of information and analysis on the global ulcerative colitis (UC) market. The report identifies the key trends shaping and driving the global UC market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to change the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global UC sector.
Or
Visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|